Live Breaking News & Updates on Therapeutically Viable Treatment

Share this article
Share this article
SEATTLE, Jan. 20, 2021 /PRNewswire/  Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company s 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults. INP104 is dihydroergotamine mesylate (DHE) delivered directly into the vascular-rich upper nasal space using Impel s proprietary Precision Olfactory Delivery (POD®) technology. If approved, INP104 will be marketed under the trade name, TRUDHESA™, in the U.S. and will become the first and only therapy to utilize the POD technology, a novel delivery system that specifically targets the vascular-rich upper nasal space. ....

Acute Treatment Of Migraine , Accepts Trade Name , Spending Approval , Lead Candidate , Proprietary Precision Olfactory Delivery , Only Delivery System , Vascular Rich Upper Nasal Space , Therapeutically Viable Treatment , Impel Neuropharma , எடுப்போசை சிகிச்சை ஆஃப் ஒற்றைத் தலைவலி , நிலுவையில் உள்ளது ஒப்புதல் , வழி நடத்து வேட்பாளர் , மட்டும் டெலிவரி அமைப்பு , வாஸ்குலர் பணக்கார மேல் நாசி இடம் ,